首页> 美国卫生研究院文献>Springer Open Choice >Osteopenia: A Diagnostic and Therapeutic Challenge
【2h】

Osteopenia: A Diagnostic and Therapeutic Challenge

机译:骨质减少症:诊断和治疗挑战

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We discussed whether we are able to select a subgroup of patients with osteopenia having a high fracture risk, in which anti-osteoporotic drug treatment can be advocated. We concluded that in individuals in whom, based on clinical risk factors, a dual-energy x-ray absorptiometry (DXA) was performed in which osteopenia was diagnosed, anti-osteoporotic treatment should be prescribed in those patients with prevalent vertebral fractures, and in patients chronically using glucocorticoids, in a dosage of 7.5 mg per day or more. Although recent developments with regard to high-resolution imaging techniques (eg, peripheral quantitative computed tomography) seem to be promising, until now they do not provide substantial more reliable information than DXA in the prediction of fractures. We think that more data are urgently needed, since safe and effective drugs are available, but there is uncertainty to which patients with osteopenia these drugs should be prescribed.
机译:我们讨论了我们是否能够选择具有高骨折风险的骨质疏松症患者亚组,其中可以倡导抗骨质疏松药物治疗。我们得出的结论是,根据临床风险因素,对诊断出骨质减少的患者进行了双能X线骨密度仪(DXA)的诊断,对于那些普遍存在椎体骨折的患者,应行抗骨质疏松治疗,长期使用糖皮质激素的患者,每天剂量为7.5 mg或更高。尽管关于高分辨率成像技术(例如,外围定量计算机断层扫描)的最新发展似乎是有希望的,但是直到现在,在骨折预测中,它们还没有提供比DXA更可靠的信息。我们认为,由于已有安全有效的药物,因此迫切需要更多数据,但是对于哪些骨质疏松症患者应开这些药物尚不确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号